Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells.
Neoplasma
; 53(1): 1-8, 2006.
Article
en En
| MEDLINE
| ID: mdl-16416005
ABSTRACT
Glucosylceramide synthase (GCS), the enzyme that converts ceramide to glucosylceramide, induce multidrug resistance (MDR) in cancer cells. Recently, RNA interference (RNAi) is a powerful strategy for gene therapy by introducing double-stranded RNA and leading to the sequence-specific destruction. We have designed two different short hairpin RNAs (shRNAs) targeting GCS and introduced them into adriamycin- resistant human breast cancer cells (MCF-7/AdrR cells) to inhibit GCS expression. The results demonstrated that the shRNAs targeting GCS decreased GCS mRNA, abolished GCS protein levels and restored the sensitivity of MCF-7/AdrR cells to several antineoplastic drugs. This study revealed that this approach can reverse MDR effectively and it may be applicable to cancer patients as a specific means to restore the sensitivity to chemotherapy.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Resistencia a Múltiples Medicamentos
/
Resistencia a Antineoplásicos
/
Interferencia de ARN
/
Glucosiltransferasas
Límite:
Female
/
Humans
Idioma:
En
Revista:
Neoplasma
Año:
2006
Tipo del documento:
Article
País de afiliación:
China